Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.73 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8660656 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| Cetrimonium SCHEMBL584090 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| Hydrochloric Acid SCHEMBL1029164 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| Hydrochloric Acid SCHEMBL1029166 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| Cetrimonium SCHEMBL584088 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| Hydrochloric Acid SCHEMBL313867 | 1.00 | DNM1 (0.73) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| SCHEMBL3802505 | 0.98 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| SCHEMBL4047250 | 0.98 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| SCHEMBL6549116 | 0.98 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52ENPP2 | |
| SCHEMBL157763 | 0.98 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289990-A1 | COMPOSITIONS AND METHODS FOR IRON CHELATION | SOLUGEN, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-12338392-B2 | Compositions and methods for iron chelation | SOLUGEN, INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-12319869-B2 | Compositions and methods for reducing injection pressure in resource recovery operations | SOLUGEN, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-11929257-B2 | Etching solution and method for aluminum nitride | VERSUM MATERIALS US, LLC (US) | 2024-03-12 | — | — | US | claimed |
| US-20230183553-A1 | COMPOSITIONS AND METHODS FOR IRON CHELATION | SOLUGEN, INC. (US) | 2023-06-15 | — | — | US | claimed |
| US-20230183549-A1 | COMPOSITIONS AND METHODS FOR REDUCING INJECTION PRESSURE IN RESOURCE RECOVERY OPERATIONS | SOLUGEN, INC. (US) | 2023-06-15 | — | — | US | claimed |
| US-20220367199-A1 | ETCHING SOLUTION AND METHOD FOR ALUMINUM NITRIDE | VERSUM MATERIALS US, LLC (US) | 2022-11-17 | — | — | US | claimed |
| WO-2021257873-A1 | COMPOSITIONS AND METHODS FOR REDUCING INJECTION PRESSURE IN RESOURCE RECOVERY OPERATIONS | SOLUGEN, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| WO-2021253006-A1 | COMPOSITIONS AND METHODS FOR IRON CHELATION | SOLUGEN, INC. (US) | 2021-12-16 | — | — | WO | claimed |
| CN-111621281-A | In-situ self-steering WAG method | 沙特阿拉伯石油公司 | 2020-09-04 | — | — | CN | claimed |
| WO-2001051767-A2 | ADDITION OF SOLIDS TO GENERATE VISCOSITY DOWNHOLE | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2001-07-19 | — | — | WO | claimed |
| US-20260042956-A1 | METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS | SCHLUMBERGER TECHNOLOGY CORPORATION | 2026-02-12 | — | — | US | disclosed |
| US-20250289990-A1 | COMPOSITIONS AND METHODS FOR IRON CHELATION | SOLUGEN, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250237017-A1 | NON-SHEAR SENSITIVE SURFACE SOFTENING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2025-07-24 | — | — | US | disclosed |
| US-12338392-B2 | Compositions and methods for iron chelation | SOLUGEN, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-1994009852-A1 | VISCOELASTIC SURFACTANT BASED FOAM FLUIDS | THE DOW CHEMICAL COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5258137-A | MIXTURE OF SURFACTANT THICKENER, A SURFACTANT CAPABLE OF FORMING A FOAM AND AN AQUEOUS LIQUID | THE DOW CHEMICAL COMPANY (US) | 1993-11-02 | — | — | US | disclosed |
| US-4790958-A | PRECIPITATION BY SUBSTITUTED AMMONIUM, PHOSPHONIUM OR SULFONIUM IONS; THICKENING | THE DOW CHEMICAL COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4631187-A | Hair treating composition containing a quaternary ammonium compound containing an erucyl group | S.C. JOHNSON & SON, INC. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0104653-A2 | Hair care composition | S.C. JOHNSON & SON, INC. (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042956-A1 | METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS | YAP1, S100A10, FOXM1 | ACHE 2809/4885DNM1 925/4885APAF1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.